Johnson & Johnson to Acquire Firefly Bio for $1 Billion to Expand Oncology Pipeline

Gelonghui, June 8 | Johnson & Johnson will acquire biotechnology company Firefly Bio for $1 billion in cash, aiming to expand its oncology drug pipeline. Firefly’s Firelink platform utilizes antibodies to deliver a protein-degrading drug directly to cancer cells. Johnson & Johnson stated that this approach better protects healthy tissues while attacking tumors compared to existing therapies.